Abstract CT219: A randomized, double-blind, placebo-controlled Phase 2 study of mifomelatide (TCMCB07) in patients with newly diagnosed metastatic colorectal cancer undergoing chemotherapy: The Paradox Trial
Michael B. Sawyer(University of Alberta), Daniel L. Marks(BioFluidica (United States)), Barry A. Badeau(University of Washington), Meghan M. Joly(UL Research Institutes), William Riedl(UL Research Institutes), E. Zhang(UL Research Institutes), Jillian L. Seiler(UL Research Institutes), Russell Potterfield(UL Research Institutes), Allison Gardner(UL Research Institutes), Brad Studnitzer(UL Research Institutes), LuAnn Sabounjian(UL Research Institutes)
Cited by 0
Related Papers
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
|Annals of Oncology|2022|253
Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic–pituitary–adrenal axis
|The Journal of Experimental Medicine|2011|203